Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726505 · ClinicalTrials.gov registry record · Phase 1
Renal Mechanism of Action/Splay vs. TmG
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00726505 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1 participants.
The verdict
NCT00726505, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus
Interventions
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726505
The ClinicalTrials.gov registry entry for NCT00726505 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dapagliflozin is the first listed.
NCT00726505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726505 about?
NCT00726505 is a clinical study titled "Renal Mechanism of Action/Splay vs. TmG". The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus
What is the current status of trial NCT00726505?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00726505?
The interventions under investigation include: Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00726505?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.